Prevention RFP - Alzheimer's Drug Discovery Foundation
Forecasted
Prevention RFP - Alzheimer's Drug Discovery Foundation supports researchers and clinicians conducting human studies of targeted interventions, combination therapies, and drug choices to reduce dementia risk.
Browse similar grants
Funder: Alzheimer's Drug Discovery Foundation
Due Dates (Anticipated): December 2026 (Invited Full Proposal)
Funding Amounts: Up to $5,000,000 for clinical trials; multi-year support
Summary: Supports human studies testing targeted interventions, combination therapies, and comparative drug effectiveness to reduce Alzheimer’s disease and dementia risk.
Key Information: Funding is a mission-related investment requiring return on investment based on scientific and/or business milestones.
Description
The Alzheimer’s Drug Discovery Foundation (ADDF) supports human research investigating whether the use or choice of interventions can reduce the risk of Alzheimer’s disease or other dementias. The Prevention RFP covers precision prevention and risk reduction, combination therapy studies, and comparative effectiveness research. Supported approaches include randomized controlled trials, epidemiological studies, and long-term follow-up of successfully completed prevention trials.
The program focuses on mechanism-specific interventions for people with dementia risk factors and on therapies targeting the biology of aging. Outcomes may include cognition, neuroimaging, and fluid biomarkers. Novel, repurposed, and repositioned drugs, natural products, supplements, and devices are considered. ADDF prioritizes interventions with composition-of-matter intellectual property, concrete plans to develop new intellectual property, or a promising commercial path.
